Myriad Genetics, Inc. MYGN
Updated: 9 Aug 2026
No signal published yet
We already track Myriad Genetics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Myriad Genetics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Myriad Genetics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 30, 2026, Myriad Genetics reported its second-quarter 2026 financial results, with revenue declining 11% year-over-year to $190.7 million. The company also lowered its full-year 2026 revenue guidance to $770–$790 million, citing reimbursement and collection challenges.
What Firelda Watch includes for Myriad Genetics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Myriad Genetics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Myriad Genetics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more